The landscape of diabetes care is evolving with the emergence of transdermal GLP-1 delivery . These convenient delivery systems offer a likely simpler alternative to injections for individuals managing diabetes mellitus type 2 . They deliver a GLP-1 agonist directly through the epidermis, circumventing the requirement for regular injections and pos